{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:55:09Z","timestamp":1789520109539,"version":"build-2803163510"},"reference-count":120,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA246130"],"award-info":[{"award-number":["R01CA246130"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR160019"],"award-info":[{"award-number":["RR160019"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The therapeutic landscape for the treatment of cancer has evolved significantly in recent decades, aided by the development of effective oncology drugs. However, many cancer drugs are often poorly tolerated by the body and in particular the cardiovascular system, causing adverse and sometimes fatal side effects that negate the chemotherapeutic benefits. The prevalence and severity of chemotherapy-induced cardiotoxicity warrants a deeper investigation of the mechanisms and implicating factors in this phenomenon, and a consolidation of scientific efforts to develop mitigating strategies. Aiding these efforts is the emergence of induced pluripotent stem cells (iPSCs) in recent years, which has allowed for the generation of iPSC-derived cardiomyocytes (iPSC-CMs): a human-based, patient-derived, and genetically variable platform that can be applied to the study of chemotherapy-induced cardiotoxicity and beyond. After surveying chemotherapy-induced cardiotoxicity and the associated chemotherapeutic agents, we discuss the use of iPSC-CMs in cardiotoxicity modeling, drug screening, and other potential applications. Improvements to the iPSC-CM platform, such as the development of more adult-like cardiomyocytes and ongoing advances in biotechnology, will only enhance the utility of iPSC-CMs in both basic science and clinical applications.<\/jats:p>","DOI":"10.3390\/cells10112823","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T14:37:48Z","timestamp":1634827068000},"page":"2823","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cardiotoxicity of Antineoplastic Therapies and Applications of Induced Pluripotent Stem Cell-Derived Cardiomyocytes"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2209-1236","authenticated-orcid":false,"given":"Mo-Fan","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA"},{"name":"The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1453-8314","authenticated-orcid":false,"given":"Lon Kai","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA"},{"name":"Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8029-7323","authenticated-orcid":false,"given":"Yi-Hung","family":"Chen","sequence":"additional","affiliation":[{"name":"Department and Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei 112, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-8913","authenticated-orcid":false,"given":"Ruiying","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2387-597X","authenticated-orcid":false,"given":"Dung-Fang","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA"},{"name":"The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA"},{"name":"Center for Stem Cell and Regenerative Medicine, The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA"},{"name":"Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102034","DOI":"10.1016\/j.scr.2020.102034","article-title":"The EBiSC iPSC bank for disease studies","volume":"49","author":"Steeg","year":"2020","journal-title":"Stem Cell Res."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Olgasi, C., Cucci, A., and Follenzi, A. (2020). iPSC-Derived liver organoids: A journey from drug screening, to disease modeling, arriving to regenerative medicine. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176215"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Chang, C.Y., Ting, H.-C., Liu, C.-A., Su, H.-L., Chiou, T.-W., Lin, S.-Z., Harn, H.-J., and Ho, T.-J. (2020). Induced pluripotent stem cell (iPSC)-based neurodegenerative disease models for phenotype recapitulation and drug screening. Molecules, 25.","DOI":"10.3390\/molecules25082000"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1161\/CIRCRESAHA.117.311080","article-title":"Induced pluripotent stem cells 10 years later: For cardiac applications","volume":"120","author":"Yoshida","year":"2017","journal-title":"Circ. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: An overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global cancer incidence and mortality rates and trends\u2014An update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/cvr\/cvz024","article-title":"Personalized medicine in cardio-oncology: The role of induced pluripotent stem cell","volume":"115","author":"Sayed","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1161\/RES.0000000000000291","article-title":"Use of human induced pluripotent stem cell-derived cardiomyocytes in preclinical cancer drug cardiotoxicity testing: A scientific statement from the american heart association","volume":"125","author":"Gintant","year":"2019","journal-title":"Circ. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1152\/physrev.00036.2015","article-title":"Human induced pluripotent stem cells as a platform for personalized and precision cardiovascular medicine","volume":"96","author":"Matsa","year":"2016","journal-title":"Physiol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Doss, M.X., and Sachinidis, A. (2019). Current challenges of iPSC-based disease modeling and therapeutic implications. Cells, 8.","DOI":"10.3390\/cells8050403"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrd.2016.245","article-title":"Induced pluripotent stem cell technology: A decade of progress","volume":"16","author":"Shi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"25333","DOI":"10.1038\/srep25333","article-title":"Modeling doxorubicin-induced cardiotoxicity in human pluripotent stem cell derived-cardiomyocytes","volume":"6","author":"Maillet","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/msb.2012.1","article-title":"Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1\/S arrest after genotoxic stress","volume":"8","author":"Tentner","year":"2012","journal-title":"Mol. Syst. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nature09005","article-title":"Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome","volume":"465","author":"Sevilla","year":"2010","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jacc.2014.04.057","article-title":"Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing","volume":"64","author":"Wang","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2016.07.779","article-title":"Patient-specific and genome-edited induced pluripotent stem cell-derived cardiomyocytes elucidate single-cell phenotype of brugada syndrome","volume":"68","author":"Liang","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/ncb3411","article-title":"iPSC-derived cardiomyocytes reveal abnormal TGF-beta signalling in left ventricular non-compaction cardiomyopathy","volume":"18","author":"Kodo","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"130ra47","DOI":"10.1126\/scitranslmed.3003552","article-title":"Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy","volume":"4","author":"Sun","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.stem.2015.04.020","article-title":"Epigenetic regulation of phosphodiesterases 2A and 3A underlies compromised beta-adrenergic signaling in an iPSC model of dilated cardiomyopathy","volume":"17","author":"Wu","year":"2015","journal-title":"Cell Stem Cell."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1161\/CIRCRESAHA.116.309948","article-title":"A comprehensive TALEN-based knockout library for generating human-induced pluripotent stem cell-based models for cardiovascular diseases","volume":"120","author":"Karakikes","year":"2017","journal-title":"Circ. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.stem.2012.10.010","article-title":"Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells","volume":"12","author":"Lan","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jchf.2012.09.001","article-title":"The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients","volume":"1","author":"Hall","year":"2013","journal-title":"JACC Heart Fail."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1023\/A:1011252132478","article-title":"Incidence and risk factors of preparation errors in a centralized cytotoxic preparation unit","volume":"23","author":"Limat","year":"2001","journal-title":"Pharm. World Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3389\/fcell.2020.00434","article-title":"Molecular mechanisms of cardiomyocyte death in drug-induced cardiotoxicity","volume":"8","author":"Ma","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejphar.2017.10.043","article-title":"Molecular mechanism of doxorubicin-induced cardiomyopathy\u2013An update","volume":"818","author":"Renu","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s00018-010-0288-8","article-title":"Crossing paths: Interactions between the cell death machinery and growth factor survival signals","volume":"67","author":"Brumatti","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2015.2","article-title":"DNA damage and the balance between survival and death in cancer biology","volume":"16","author":"Roos","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1089\/ars.2012.4905","article-title":"Regulation of the intrinsic apoptosis pathway by reactive oxygen species","volume":"19","author":"Wu","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10495-014-1060-6","article-title":"Death effecter domain for the assembly of death-inducing signaling complex","volume":"20","author":"Yang","year":"2015","journal-title":"Apoptosis"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"11293","DOI":"10.1021\/bi971475e","article-title":"Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin","volume":"36","author":"Martasek","year":"1997","journal-title":"Biochemistry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.freeradbiomed.2006.11.013","article-title":"Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH","volume":"42","author":"Deng","year":"2007","journal-title":"Free Radic. Biol. Med."},{"key":"ref_37","first-page":"4592","article-title":"Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio","volume":"62","author":"Childs","year":"2002","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1476-5381.2011.01208.x","article-title":"Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity","volume":"163","author":"Spagnuolo","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"36698","DOI":"10.18632\/oncotarget.9162","article-title":"Matricellular protein CCN1 mediates doxorubicin-induced cardiomyopathy in mice","volume":"7","author":"Hsu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jir.2006.0161","article-title":"Change in TNF-\u03b1 receptor expression is a relevant event in doxorubicin-induced H9c2 cardiomyocyte cell death","volume":"27","author":"Chiosi","year":"2007","journal-title":"J. Interf. Cytokine Res."},{"key":"ref_41","first-page":"509","article-title":"Potassium channels and autophagy","volume":"69","author":"Yang","year":"2017","journal-title":"Sheng Li Xue Bao"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.febslet.2010.01.017","article-title":"mTOR regulation of autophagy","volume":"584","author":"Jung","year":"2010","journal-title":"FEBS Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncb2152","article-title":"AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1","volume":"13","author":"Kim","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ludke, A., Akolkar, G., Ayyappan, P., Sharma, A.K., and Singal, P.K. (2017). Time course of changes in oxidative stress and stress-induced proteins in cardiomyocytes exposed to doxorubicin and prevention by vitamin C. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179452"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2590676","DOI":"10.1155\/2017\/2590676","article-title":"Apigenin attenuates adriamycin-induced cardiomyocyte apoptosis via the PI3K\/AKT\/mTOR pathway","volume":"2017","author":"Yu","year":"2017","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.toxlet.2018.04.034","article-title":"HMGB1 contributes to adriamycin-induced cardiotoxicity via up-regulating autophagy","volume":"292","author":"Luo","year":"2018","journal-title":"Toxicol. Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"21993","DOI":"10.1074\/jbc.M111.225805","article-title":"Caloric restriction mimetic 2-deoxyglucose antagonizes doxorubicin-induced cardiomyocyte death by multiple mechanisms","volume":"286","author":"Chen","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"H1466","DOI":"10.1152\/ajpheart.00795.2008","article-title":"Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro","volume":"296","author":"Mukhopadhyay","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00280-015-2879-4","article-title":"Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy","volume":"76","author":"Fulbright","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"748524","DOI":"10.1155\/2014\/748524","article-title":"Nrf2 deficiency exaggerates doxorubicin-induced cardiotoxicity and cardiac dysfunction","volume":"2014","author":"Li","year":"2014","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cbi.2008.09.012","article-title":"Reactive oxygen species-independent apoptosis in doxorubicin-treated H9c2 cardiomyocytes: Role for heme oxygenase-1 down-modulation","volume":"177","author":"Bernuzzi","year":"2009","journal-title":"Chem. Biol. Interact."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11010-016-2653-x","article-title":"Oxidative stress does not play a primary role in the toxicity induced with clinical doses of doxorubicin in myocardial H9c2 cells","volume":"413","author":"Rharass","year":"2016","journal-title":"Mol. Cell. Biochem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"475","DOI":"10.7326\/0003-4819-81-4-475","article-title":"Adriamycin cardiotoxicity in man","volume":"81","author":"Rinehart","year":"1974","journal-title":"Ann. Intern. Med."},{"key":"ref_54","first-page":"59","article-title":"Chemotherapy-induced cardiotoxicity","volume":"8","author":"Florescu","year":"2013","journal-title":"Maedica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nm.4087","article-title":"Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity","volume":"22","author":"Burridge","year":"2016","journal-title":"Nat. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s00204-015-1623-5","article-title":"Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: An in vitro repeated exposure toxicity approach for safety assessment","volume":"90","author":"Chaudhari","year":"2016","journal-title":"Arch. Toxicol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/toxsci\/kfu150","article-title":"Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes","volume":"141","author":"Eldridge","year":"2014","journal-title":"Toxicol. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/nrcardio.2015.133","article-title":"Cardiotoxicity of anticancer treatments","volume":"12","author":"Ewer","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e000665","DOI":"10.1161\/JAHA.113.000665","article-title":"Cancer therapy-induced cardiotoxicity: Basic mechanisms and potential cardioprotective therapies","volume":"3","author":"Hahn","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1089\/adt.2015.659","article-title":"High-Content assay multiplexing for toxicity screening in induced pluripotent stem cell-derived cardiomyocytes and hepatocytes","volume":"13","author":"Grimm","year":"2015","journal-title":"Assay Drug Dev. Technol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1161\/CIRCULATIONAHA.113.001883","article-title":"Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity","volume":"127","author":"Liang","year":"2013","journal-title":"Circulation"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1161\/CIRCULATIONAHA.112.000570","article-title":"Screening drug-induced arrhythmia using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays","volume":"128","author":"Navarrete","year":"2013","journal-title":"Circulation"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.2459\/JCM.0000000000000376","article-title":"Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy","volume":"17","author":"Madeddu","year":"2016","journal-title":"J. Cardiovasc. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s13287-020-01984-1","article-title":"Melphalan induces cardiotoxicity through oxidative stress in cardiomyocytes derived from human induced pluripotent stem cells","volume":"11","author":"Liu","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1161\/CIRCULATIONAHA.118.037357","article-title":"Human-induced pluripotent stem cell model of trastuzumab-induced cardiac dysfunction in patients with breast cancer","volume":"139","author":"Kitani","year":"2019","journal-title":"Circulation"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40169-016-0133-2","article-title":"The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes","volume":"6","author":"Necela","year":"2017","journal-title":"Clin. Transl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.toxlet.2018.01.001","article-title":"Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes","volume":"285","author":"Kurokawa","year":"2018","journal-title":"Toxicol. Lett."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.cels.2019.03.009","article-title":"Adaptation of human iPSC-derived cardiomyocytes to tyrosine kinase inhibitors reduces acute cardiotoxicity via metabolic reprogramming","volume":"8","author":"Wang","year":"2019","journal-title":"Cell Syst."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.taap.2015.03.008","article-title":"Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types","volume":"285","author":"Doherty","year":"2015","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/toxsci\/kfu215","article-title":"A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity","volume":"143","author":"Talbert","year":"2015","journal-title":"Toxicol. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1126\/scitranslmed.aaf2584","article-title":"High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells","volume":"9","author":"Sharma","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e68714","DOI":"10.7554\/eLife.68714","article-title":"Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes","volume":"10","author":"Grafton","year":"2021","journal-title":"eLife"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: A systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/bmj.284.6308.19-a","article-title":"Perverse T waves and chronic beta-blocker treatment","volume":"284","author":"Griffith","year":"1982","journal-title":"Br. Med. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"100052","DOI":"10.1016\/j.xcrm.2020.100052","article-title":"Human iPSC-derived cardiomyocytes are susceptible to SARS-CoV-2 infection","volume":"1","author":"Sharma","year":"2020","journal-title":"Cell Rep. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"607364","DOI":"10.3389\/fphar.2021.607364","article-title":"Building multi-dimensional induced pluripotent stem cells-based model platforms to assess cardiotoxicity in cancer therapies","volume":"12","author":"Thomas","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1161\/RES.0000000000000473","article-title":"Preclinical models of cancer therapy-associated cardiovascular toxicity: A scientific statement from the American Heart Association","volume":"129","author":"Asnani","year":"2021","journal-title":"Circ. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.18.01160","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update","volume":"37","author":"Burstein","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/CMAR.S77400","article-title":"Cancer therapy and cardiovascular risk: Focus on bevacizumab","volume":"7","author":"Economopoulou","year":"2015","journal-title":"Cancer Manag. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0002-9343(77)90315-1","article-title":"Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases","volume":"62","author":"Rozencweig","year":"1977","journal-title":"Am. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/1873-3468.12956","article-title":"Mitochondrial DNA damage and reactive oxygen species in neurodegenerative disease","volume":"592","author":"Nissanka","year":"2018","journal-title":"FEBS Lett."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/carcin\/bgn250","article-title":"Base excision repair of oxidative DNA damage and association with cancer and aging","volume":"30","author":"Maynard","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"101084","DOI":"10.1016\/j.redox.2018.101084","article-title":"ROS and the DNA damage response in cancer","volume":"25","author":"Srinivas","year":"2019","journal-title":"Redox Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase IIbeta mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1203\/PDR.0b013e318184d732","article-title":"A mouse model for juvenile doxorubicin-induced cardiac dysfunction","volume":"64","author":"Zhu","year":"2008","journal-title":"Pediatr. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/187152506775268785","article-title":"Cardiotoxicity of 5-fluorouracil","volume":"4","author":"Alter","year":"2006","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1758835918780140","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: A review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/med.1022","article-title":"Tyrosine kinase inhibitors: From rational design to clinical trials","volume":"21","author":"Traxler","year":"2001","journal-title":"Med. Res. Rev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/02841860903229124","article-title":"Cardiotoxicity induced by tyrosine kinase inhibitors","volume":"48","author":"Orphanos","year":"2009","journal-title":"Acta Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"352182","DOI":"10.4061\/2011\/352182","article-title":"Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer","volume":"2011","author":"Fiszman","year":"2011","journal-title":"Int. J. Breast Cancer"},{"key":"ref_92","first-page":"13","article-title":"Trastuzumab-mediated cardiotoxicity: Current understanding, challenges, and frontiers","volume":"1","author":"Mohan","year":"2018","journal-title":"Antib. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"ElZarrad, M.K., Mukhopadhyay, P., Mohan, N., Hao, E., Dokmanovic, M., Hirsch, D.S., Shen, Y., Pacher, P., and Wu, W.J. (2013). Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0079543"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/1535-7163.MCT-15-0741","article-title":"Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes","volume":"15","author":"Mohan","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkela","year":"2006","journal-title":"Nat. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_99","first-page":"6","article-title":"Managing cardiotoxicity associated with immune checkpoint inhibitors","volume":"5","author":"Upadhrasta","year":"2019","journal-title":"Chron. Dis. Transl. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/01.CCM.0000261893.72811.0F","article-title":"Predictive value of N-terminal pro-brain natriuretic peptide in severe sepsis and septic shock","volume":"35","author":"Varpula","year":"2007","journal-title":"Crit. Care Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1111\/bph.13713","article-title":"Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes","volume":"174","author":"Kopljar","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/toxsci\/kfw200","article-title":"Comprehensive translational assessment of human-induced pluripotent stem cell derived cardiomyocytes for evaluating drug-induced arrhythmias","volume":"155","author":"Blinova","year":"2017","journal-title":"Toxicol. Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.taap.2018.07.020","article-title":"RNA sequence analysis of inducible pluripotent stem cell-derived cardiomyocytes reveals altered expression of DNA damage and cell cycle genes in response to doxorubicin","volume":"356","author":"Reyes","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s00204-020-02711-8","article-title":"GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: Establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes","volume":"94","author":"Karhu","year":"2020","journal-title":"Arch. Toxicol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1038\/s41596-018-0076-8","article-title":"Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity","volume":"13","author":"Sharma","year":"2018","journal-title":"Nat. Protoc."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e33480","DOI":"10.7554\/eLife.33480","article-title":"Determining the genetic basis of anthracycline-cardiotoxicity by molecular response QTL mapping in induced cardiomyocytes","volume":"7","author":"Knowles","year":"2018","journal-title":"eLife"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/toxsci\/kfy012","article-title":"Expression profiling of human pluripotent stem cell-derived cardiomyocytes exposed to doxorubicin-integration and visualization of multi-omics data","volume":"163","author":"Holmgren","year":"2018","journal-title":"Toxicol. Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"10363","DOI":"10.1038\/s41598-020-65979-x","article-title":"Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes","volume":"10","author":"Christidi","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.jacc.2016.01.083","article-title":"Translation of human-induced pluripotent stem cells: From clinical trial in a dish to precision medicine","volume":"67","author":"Sayed","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/cpt.1311","article-title":"Pediatric anthracycline-induced cardiotoxicity: Mechanisms, pharmacogenomics, and pluripotent stem-cell modeling","volume":"105","author":"Tripaydonis","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bjh.12516","article-title":"Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation","volume":"163","author":"Armenian","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"9287","DOI":"10.1158\/0008-5472.CAN-10-2664","article-title":"Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.stem.2017.06.005","article-title":"The evolving roles of human iPSC-derived cardiomyocytes in drug safety and discovery","volume":"21","author":"Gintant","year":"2017","journal-title":"Cell Stem Cell"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1087057115594589","article-title":"A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm","volume":"21","author":"Fermini","year":"2016","journal-title":"J. Biomol. Screen."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Smith, L.A., Cornelius, V.R., Plummer, C.J., Levitt, G., Verrill, M., Canney, P., and Jones, A. (2010). Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-337"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nrcardio.2009.154","article-title":"Cardiovascular pharmacogenomics and individualized drug therapy","volume":"6","author":"Pereira","year":"2009","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"D896","DOI":"10.1093\/nar\/gkw1133","article-title":"The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog)","volume":"45","author":"MacArthur","year":"2017","journal-title":"Nucl. Acids Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3727\/096504017X14876245096439","article-title":"Polymorphic variations associated with doxorubicin-induced cardiotoxicity in breast cancer patients","volume":"25","author":"Todorova","year":"2017","journal-title":"Oncol. Res."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/11\/2823\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:19:51Z","timestamp":1760167191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/11\/2823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":120,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["cells10112823"],"URL":"https:\/\/doi.org\/10.3390\/cells10112823","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,21]]}}}